Bacterial lipopolysaccharide (LPS)-specific antibodies in commercial human immunoglobulin preparations: Superior antibody content of an IgM- enriched product

Clinical and Experimental Immunology

Volumn 111, Issue 1, 1998, Pages 81-90

  Trautmann, M ^b,c   Held, T K ^a   Susa, M ^b   Karajan, M A ^b   Wulf, A ^b   Cross, A S ^a   Marre, R ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ULM   (Germany)

^c Dept of Med Microbiol and Hygiene ^*  (Germany)

Author keywords

Endotoxin; Immunoglobulin(s); Lipopolysaccharide

Indexed keywords

ANTIBODY; BACTERIUM LIPOPOLYSACCHARIDE; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M;

ANTIBODY SPECIFICITY; ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; GRAM NEGATIVE SEPSIS; GRAM POSITIVE BACTERIUM; IMMUNOBLOTTING; KLEBSIELLA; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; VIBRIO CHOLERAE;

ANTIBODIES, BACTERIAL; DRUG CONTAMINATION; HUMANS; IMMUNOGLOBULIN M; LIPOPOLYSACCHARIDES;

EID: 0031929252     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1998.00445.x     Document Type: Article

References (51)

1. Horan T, Culver D, Jarvis W et al. Pathogens causing nosocomial infections. Preliminary data from the National Nosocomial Infections Surveillance System. Antimicrob Newsletter 1988; 5:65-7.
2. Arpi M, Renneberg J, Andersen HK, Nielsen B, Larsen SO. Bacteremia at a Danish University Hospital during a 25-year period (1968-1992). Scand J Infect Dis 1995; 27:245-51.
3. Opal SM. Clinical trials of novel therapeutic agents: why did they fail? In: Vincent JL, ed. Yearbook of intensive care and emergency medicine. Berlin: Springer, 1995:425-36.
4. Schmidt RE, Hartlapp JH, Niese D, Illiger HJ, Stroehmann I. Reduction of infection frequency by intravenous gammaglobulins during intensive induction therapy for small cell carcinoma. Infection 1984; 12:167-70.
5. Glinz W, Grob PJ, Nydegger UE et al. Polyvalent immunoglobulins for prophylaxis of bacterial infections in patients following multiple trauma. Intensive Care Med 1985; 11:288-94.
6. Graham-Pole J, Camitta B, Casper J et al. Intravenous immunoglobulin may lessen all forms of infection in patients receiving allogeneic bone marrow transplantation for acute lymphoblastic leukemia: a pediatric oncology group study. Bone Marrow Transplant 1988; 3:559-66.
7. Sullivan KM, Kopecky KJ, Jocom J et al. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med 1990; 323:705-12.
8. The intravenous immunoglobulin collaborative study group. Prophylactic intravenous administration of standard immune globulin as compared with core-lipopolysaccharide immune globulin in patients at high risk of postsurgical infection. N Engl J Med 1992; 327:234-40.
9. Baker CJ, Melish ME, Hall RT, Casto DT, Vasan U, Givner LB, and the Multicenter Group for the Study of Immune Globulin in Neonates. Intravenous immune globulin for the prevention of nosocomial infection in low-birth-weight neonates. N Engl J Med 1992; 327:213-9.
10. Sidiropoulos D, Bohme U, von Muralt G, Morell A, Barandun S. Immunglobulinsubstitution bei der Behandlung der neonatalen Sepsis. Schweiz Med Wochenschr 1981; 111:1649-5.5.
11. Weisman LE, Stoll BJ, Kueser TJ et al. Intravenous immune globulin therapy for early-onset sepsis in premature neonates. J Pediatr 1992; 121:434-43.
12. Haque KN, Zaidi MH. IgM-enriched intravenous immunoglobulin therapy in neonatal sepsis. Am J Dis Child 1988; 142:1293-6.
13. Schedel I, Dreikhausen U, Nentwig B et al. Treatment of Gram-negative septic shock with an immunoglobulin preparation: a prospective, randomized trial. Crit Care Med 1991; 19:1104-13.
14. Jackson SK, Barton J, Barnes RA, Poynton CH, Fegan C. Effect of IgM-enriched intravenous immunoglobulin (Pentaglobin) on endotoxaemia and anti-endotoxin antibodies in bone marrow transplantation. Eur J Clin Invest 1993; 23:540-5.
15. Cross AS, Opal SM. Endotoxin's role in Gram-negative bacterial infection. Curr Opin Infect Dis 1995; 8:156-63.
16. Westphal O, Jann K. Bacterial lipopolysaccharides: extraction with phenol-water and further applications of the procedure. Methods Carbohydr Chem 1965; 5:83-91.
17. Schiff ED, Wass CA, Cryz SJ Jr, Cross AS, Kim KS. Estimation of protective levels of anti-O-specilic lipopolysaccharide immunoglobulin G antibody against experimental Escherichia coli infection. Infect Immun 1993; 61:975-80.
18. Cross A, Artenstein A, Que J et al. Safety and immunogenicity of a polyvalent Escherichia coli vaccine in human volunteers. J Infect Dis 1994; 170:834-40.
19. Sidberry H, Kaufman B, Wright DR, Sadoff J. Immunoenzymatic analysis by monoclonal antibodies of bacterial lipopolysaccharides after transfer to nitrocellulose. J Immunol Methods 1985; 76:299-305.
20. 4. Nature 1970; 227:680-5.
21. Tsai CM, Frasch CE. A sensitive silver stain for detecting lipopolysaccharides in polyacrylamide gels. Anal Biochem 1982; 119:115-9.
22. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 1979; 76:4350-4.
23. Ochs HD, Lee ML, Fischer SH, Delson ES, Chang BS, Wedgwood RJ. Self-infusion of intravenous immunoglobulin by immunodeficient patients at home. J Infect Dis 1987; 156:652-4.
24. Pennington JE, Small GJ, Lostrom ME, Pier GB. Polyclonal and monoclonal antibody therapy for experimental Pseudomonas aeruginosa pneumonia. Infect Immun 1986; 54:239-14.
25. Kim KS, Cross AS, Zollinger W, Sadoff J. Prevention and therapy of experimental Escherichia coli infection with monoclonal antibody. Infect Immun 1985; 50:734-7.
26. Cohen J. Intravenous immunoglobulin (IVIG) for Gram-negative infection a critical review. J Hosp Infect 1988; 12(Suppl. D):47-54.
27. Werdan K, Pilz G. Supplemental immune globulins in sepsis: a critical appraisal. Clin Exp Immunol 1996; 104(Suppl. 1):83-90.
28. Dominioni L, Dionigi R, Zanello M et al. Effects of high-dose IgG on survival of surgical patients with sepsis scores of 20 or greater. Arch Surg 1991; 126:236-40.
29. European Pharmacopoeia 1997:0918. Human normal immunoglobulin for intravenous administration. Stuttgart: Wiss. Verlagsgesellschaft, 1997:963-5.
30. Abe Y, Horiochi A, Miyake M, Kimura S. Anti-cytokine nature of natural human immunoglobulin: one possible mechanism of the clinical effect of intravenous immunoglobulin therapy. Immunol Rev 1994; 139:5-17.
31. Trautmann M, Karajan MA, Susa M, Marre R, Gansauge F. Intravenous immunoglobulins inhibit LPS-induced TNFα-release from human monocytic cells. Proceedings of the 4th International Congress on the Immune Consequences of Trauma, Shock and Sepsis, Munich (Germany), March 4-8, 1997. Milan: Monduzzi Editore, 775-9.
32. Gaftin SL, Badsha N, Brock-Utne JG, Vorster BJ, Conradie JD. An ELISA procedure for detecting human anti-endotoxin antibodies in serum. Ann Clin Biochem 1982; 19:191-4.
33. Gaffin SL, Lachman E. The use of antilipopolysaccharide (anti-LPS) antibodies in the management of septic shock. South Afr Med J 1984; 65:158-61.
34. Fink PC, Bokelmann G, Haeckel R. Determination of antibodies against bacterial lipopolysaccharides and lipid A by immunoblotting. Immunobiol 1989; 112:57-68.
35. Hiemstra PS, Brands-Tajouili J, van Furth R. Comparison of antibody activity against various microorganisms in intravenous immunoglobulin preparations determined by ELISA and opsonic assay. J Lab Clin Med 1994; 123:241-6.
36. Ørskov F, Ørskov I. Escherichia coli O:H serotypes isolated from human blood. Acta Pathol Microbiol Scand B 1975; 30:595-600.
37. McCabe WR, Kaijser B, Olling S, Uwaydah M, Hanson LA. Escherichia coli in bacteremia: K and O antigens and serum sensitivity of strains from adults and neonates. J Infect Dis 1978; 138:33-41.
38. Devine DA, Robinson L, Roberts AP. Occurrence of K1, K5 and O antigens in Escherichia coli isolates from patients with urinary tract infections or bacteremia. J Med Microbiol 1989; 30:295-9.
39. Gransden WR, Eykyn S, Phillips I, Rowe B. Bacteremia due to Escherichia coli: a study of 861 episodes. Rev Infect Dis 1990; 12: 1008-18.
40. Olesen B, Kolmos HJ, Ørskov F, Ørskov I. A comparative study of nosocomial and community-acquired strains of Escherichia coli causing bacteraemia in a Danish University hospital. J Hosp Infect 1995; 31:295-304.
41. Pier GB, Thomas DM. Lipopolysaccharide and high-molecular-weight polysaccharide serotypes of Pseudomonas aeruginosa. J Infect Dis 1982; 145:217-23.
42. Vásquez F, Mendoza MC, Villar MH, Vindel A, Méndez FJ. Characteristics of Pseudomonas aeruginosa strains causing septicemia in a Spanish University hospital 1981-1990. Eur J Clin Microbiol Infect Dis 1992; 11:698-703.
43. Trautmann M, Ruhnke M, Rukavina T, Held T, Cross AS, Marre R, Whitfield C. O antigen seroepidemiology of Klebsiella clinical isolates and implications for immunoprophylaxis of Klebsiella infections. Clin Diagn Lab Immunol 1997; in press.
44. Shroff KE, Meslin K, Cebra JJ. Commensal enteric bacteria engender a self-limiting humoral mucosal immune response while permanently colonizing the gut. Infect Immun 1995; 63:3904-13.
45. Ørskov F, Ørskov I. Antibodies against core and O antigen epitopes of Escherichia coli O83 in rabbit antisera and in commercial human immunoglobulin. Med Microbiol Immunol 1991; 180:157-66.
46. Michael JG, Rosen FS. Association of 'natural' antibodies to Gram-negative bacteria with the gamma-1-macroglobulins. J Exp Med 1963; 118:619-26.
47. Rosen FS. The macroglobulins. New Eng J Med 1962; 267:546-50.
48. Gitlin D, Rosen FS, Michael JG. Transient 19S gamma-globulin deficiency in the newborn infant, and its significance. Pediatrics 1963; 31:197-208.
49. Scott BB, Barclay GR. Endotoxin-polymyxin complexes in an improved enzyme-linked immunosorbent assay for IgG antibodies in blood donor sera to Gram-negative endotoxin core glycolipids. Vox Sang 1987; 52:272-80.
50. Fujihara Y, Lei MG, Morrison DC. Characterization of specific binding of a human immunoglobulin M monoclonal antibody to lipopolysaccharide and its lipid A domain. Infect Immun 1993; 61:910-8.
51. McCutchan JA, Ziegler EJ. Treatment with anti Gram-negative antibodies. The Lancet 1983;ii:802-3.